Transport
Kalispell Regional Medical Center INC
Kalispell Regional Medical Center INC was paid $8.83M by Medicaid between Jan 2018 and Dec 2024, across 440 billing codes. Its largest line is 43239, Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple — 6.0% of everything it billed.
33Billing provider infoKALISPELL REGIONAL MEDICAL CENTER INC
KALISPELL, MT 59901
KALISPELL, MT 59901
33aNPI1417945627assigned 10/11/2005
33bProvider typeAmbulance
28Total paid$8.83M
24GClaims1,217,790
24DCodes billed440
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Montana
Rank by total paid#1 of 16
Median peer was paid$93K
This provider vs. median95×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ABEL, KEVIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 186,921 | $1.30M | |
| 2019 | 163,279 | $1.29M | |
| 2020 | 143,732 | $864K | |
| 2021 | 198,986 | $1.65M | |
| 2022 | 198,774 | $1.41M | |
| 2023 | 199,843 | $1.32M | |
| 2024incomplete | 126,255 | $990K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 6.0% | 3,440 | 3,278 | $528K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 21,072 | 19,293 | $480K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.1% | 19,883 | 17,221 | $366K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.8% | 12,773 | 4,386 | $338K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.5% | 14,574 | 9,342 | $313K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 5,030 | 4,551 | $310K |
| G0378 | Hospital observation service, per hour | 3.3% | 4,121 | 3,585 | $288K |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | 3.1% | 195 | 180 | $273K |
| A0430 | Ambulance service, conventional air services, transport, one way (fixed wing) | 2.9% | 195 | 166 | $255K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 6,210 | 5,413 | $234K |
| A0435 | Fixed wing air mileage, per statute mile | 2.3% | 185 | 154 | $201K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.2% | 9,594 | 3,265 | $197K |
428 more codes
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.2% | 407 | $193K |
| 80053 | Comprehensive metabolic panel | 1.7% | 69,409 | $152K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.7% | 1,002 | $150K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 3,536 | $139K |
| A0436 | Rotary wing air mileage, per statute mile | 1.6% | 198 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 68,875 | $136K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 2,618 | $131K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.5% | 1,370 | $129K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 1,195 | $125K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 1,062 | $108K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 279 | $101K |
| 88342 | 1.1% | 4,076 | $94K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,330 | $82K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,212 | $81K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19,017 | $80K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,418 | $78K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,905 | $78K |
| 80050 | General health panel | <1% | 11,184 | $74K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,730 | $74K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,403 | $72K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,647 | $71K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,786 | $70K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,903 | $68K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,123 | $67K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 3,414 | $64K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 537 | $62K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14,615 | $61K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,251 | $59K |
| 82728 | <1% | 9,482 | $58K | |
| 86140 | <1% | 11,713 | $53K | |
| 87631 | <1% | 1,470 | $48K | |
| 93320 | <1% | 914 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,510 | $45K |
| 93325 | <1% | 1,769 | $43K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 170 | $39K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,940 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,893 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,929 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 872 | $38K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 327 | $35K |
| A0434 | Specialty care transport (sct) | <1% | 112 | $35K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,818 | $35K |
| 74018 | <1% | 1,649 | $34K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,419 | $34K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 950 | $33K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,596 | $31K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,347 | $31K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,277 | $31K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 626 | $30K |
| 83690 | <1% | 11,298 | $30K | |
| 82784 | <1% | 3,777 | $29K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,738 | $29K |
| 72141 | <1% | 641 | $29K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,400 | $28K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,145 | $28K |
| 87186 | <1% | 8,681 | $28K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,484 | $28K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,966 | $27K |
| 85379 | <1% | 2,975 | $27K | |
| 84703 | <1% | 7,036 | $26K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,006 | $25K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,632 | $25K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,460 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,521 | $23K |
| 84439 | <1% | 8,814 | $22K | |
| 81025 | <1% | 3,916 | $21K | |
| 87077 | <1% | 10,573 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,517 | $20K |
| 87040 | <1% | 2,647 | $20K | |
| 85652 | <1% | 10,236 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,380 | $18K |
| 92526 | <1% | 810 | $17K | |
| 83550 | <1% | 6,157 | $16K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 848 | $16K |
| 83540 | <1% | 6,496 | $16K | |
| 76775 | <1% | 429 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,707 | $15K |
| 36000 | <1% | 4,679 | $15K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 978 | $15K |
| 80061 | Lipid panel | <1% | 19,194 | $15K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,021 | $15K |
| 81003 | <1% | 10,807 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,352 | $13K |
| 81001 | <1% | 9,708 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,961 | $13K |
| 82803 | <1% | 2,488 | $12K | |
| 73221 | <1% | 223 | $12K | |
| 76536 | <1% | 395 | $12K | |
| 96415 | <1% | 2,664 | $12K | |
| 74183 | <1% | 559 | $12K | |
| 88112 | <1% | 1,196 | $12K | |
| 87070 | <1% | 3,318 | $12K | |
| 83880 | <1% | 2,163 | $11K | |
| 88304 | <1% | 1,104 | $11K | |
| 86364 | <1% | 1,706 | $11K | |
| 88341 | <1% | 312 | $11K | |
| 73110 | <1% | 667 | $11K | |
| 83735 | <1% | 8,324 | $11K | |
| 81513 | <1% | 2,489 | $10K | |
| 73610 | <1% | 1,055 | $10K | |
| 83970 | <1% | 1,871 | $10K | |
| 77002 | <1% | 842 | $10K | |
| 30140 | <1% | 60 | $9K | |
| 96376 | <1% | 4,509 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,516 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 669 | $9K |
| A0425 | Ground mileage, per statute mile | <1% | 145 | $9K |
| 97116 | <1% | 2,114 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,638 | $8K |
| 82948 | <1% | 9,941 | $8K | |
| 73222 | <1% | 118 | $8K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 146 | $8K |
| 73630 | <1% | 896 | $8K | |
| 84484 | <1% | 8,734 | $7K | |
| 83605 | <1% | 2,187 | $7K | |
| 97162 | <1% | 1,378 | $7K | |
| 95812 | <1% | 108 | $7K | |
| 82533 | <1% | 1,531 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,950 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,350 | $7K |
| 85730 | <1% | 3,665 | $7K | |
| 99152 | <1% | 1,970 | $7K | |
| 86850 | <1% | 4,228 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,258 | $7K |
| 86900 | <1% | 4,326 | $7K | |
| 97163 | <1% | 772 | $7K | |
| 83516 | <1% | 973 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 51,867 | $6K |
| 82274 | <1% | 929 | $6K | |
| 84100 | <1% | 4,416 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,140 | $6K |
| 82607 | <1% | 4,755 | $6K | |
| 93017 | <1% | 1,650 | $6K | |
| 87481 | <1% | 4,957 | $6K | |
| 85610 | <1% | 9,673 | $6K | |
| 73562 | <1% | 757 | $5K | |
| 36430 | <1% | 35 | $5K | |
| 85027 | <1% | 14,693 | $5K | |
| 76937 | <1% | 1,598 | $5K | |
| 80076 | <1% | 1,723 | $5K | |
| 87205 | <1% | 2,553 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,067 | $5K |
| 73030 | <1% | 1,022 | $5K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 479 | $5K |
| 97597 | <1% | 545 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,071 | $5K |
| 82570 | <1% | 3,965 | $4K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,024 | $4K |
| 88307 | <1% | 714 | $4K | |
| 30520 | <1% | 13 | $4K | |
| 84436 | <1% | 678 | $4K | |
| 86003 | <1% | 46 | $4K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 98 | $4K |
| 73080 | <1% | 130 | $4K | |
| 83993 | <1% | 152 | $4K | |
| 73502 | <1% | 610 | $4K | |
| 83520 | <1% | 254 | $4K | |
| 86901 | <1% | 4,343 | $4K | |
| 87510 | <1% | 2,942 | $4K | |
| 87480 | <1% | 2,941 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,047 | $4K |
| 87660 | <1% | 2,941 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 793 | $4K |
| 96367 | <1% | 4,307 | $4K | |
| 71250 | <1% | 699 | $3K | |
| 12001 | <1% | 131 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,185 | $3K |
| 86803 | <1% | 5,279 | $3K | |
| 73130 | <1% | 450 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,880 | $3K |
| 76870 | <1% | 100 | $3K | |
| 84403 | <1% | 1,496 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,424 | $3K |
| 96411 | <1% | 137 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,555 | $3K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,781 | $3K |
| 84702 | <1% | 2,547 | $3K | |
| 82565 | <1% | 1,161 | $3K | |
| 87507 | <1% | 651 | $3K | |
| 86038 | <1% | 1,515 | $3K | |
| 86780 | <1% | 4,382 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,489 | $3K |
| 59025 | Fetal non-stress test | <1% | 2,233 | $3K |
| 82248 | <1% | 1,064 | $3K | |
| 76642 | <1% | 1,090 | $3K | |
| 95811 | <1% | 72 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,410 | $3K |
| 84146 | <1% | 1,614 | $3K | |
| 83615 | <1% | 2,232 | $3K | |
| 74160 | <1% | 85 | $2K | |
| 84402 | <1% | 764 | $2K | |
| 70491 | <1% | 71 | $2K | |
| 86431 | <1% | 1,815 | $2K | |
| 87081 | <1% | 627 | $2K | |
| 84481 | <1% | 1,878 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,326 | $2K |
| 86376 | <1% | 581 | $2K | |
| 81015 | <1% | 2,374 | $2K | |
| 83001 | <1% | 1,230 | $2K | |
| 97161 | <1% | 228 | $2K | |
| 85046 | <1% | 335 | $2K | |
| 96417 | <1% | 1,319 | $2K | |
| 87340 | <1% | 3,687 | $2K | |
| 82330 | <1% | 227 | $2K | |
| 86231 | <1% | 160 | $2K | |
| 72100 | <1% | 593 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,846 | $2K |
| 86481 | <1% | 569 | $2K | |
| 84156 | <1% | 1,963 | $2K | |
| 84550 | <1% | 2,885 | $2K | |
| 82043 | <1% | 1,916 | $2K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 1,530 | $2K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 228 | $2K |
| 86200 | <1% | 900 | $2K | |
| 97166 | <1% | 214 | $2K | |
| 82550 | <1% | 2,086 | $2K | |
| 96409 | <1% | 19 | $2K | |
| 84145 | <1% | 493 | $1K | |
| 87529 | <1% | 214 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,835 | $1K |
| 92523 | <1% | 56 | $1K | |
| 82746 | <1% | 1,480 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,137 | $1K |
| 87999 | <1% | 33 | $1K | |
| 93976 | <1% | 159 | $1K | |
| 82670 | <1% | 946 | $1K | |
| 84480 | <1% | 181 | $1K | |
| 87075 | <1% | 341 | $1K | |
| 93971 | <1% | 832 | $1K | |
| 82977 | <1% | 419 | $1K | |
| 82150 | <1% | 540 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,065 | $1K |
| 70486 | <1% | 28 | $1K | |
| 43235 | <1% | 29 | $1K | |
| 72110 | <1% | 65 | $1K | |
| 85014 | <1% | 2,099 | $1K | |
| 80074 | <1% | 591 | $970.47 | |
| 90715 | <1% | 568 | $967.22 | |
| 51701 | <1% | 540 | $922.85 | |
| 86255 | <1% | 164 | $832.11 | |
| 23350 | <1% | 112 | $821.92 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 464 | $821.81 |
| 86706 | <1% | 1,395 | $806.53 | |
| 83002 | <1% | 226 | $805.33 | |
| 89051 | <1% | 152 | $787.21 | |
| 12002 | <1% | 29 | $779.82 | |
| J3490 | Unclassified drugs | <1% | 487 | $762.90 |
| 86403 | <1% | 536 | $698.83 | |
| 73140 | <1% | 39 | $678.94 | |
| 87150 | <1% | 1,484 | $654.53 | |
| 84305 | <1% | 57 | $634.95 | |
| 84460 | <1% | 148 | $610.46 | |
| 82947 | <1% | 1,930 | $591.89 | |
| 94760 | <1% | 1,103 | $591.73 | |
| 86762 | <1% | 1,668 | $585.13 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 90 | $559.83 |
| 83655 | <1% | 69 | $558.46 | |
| 97802 | <1% | 19 | $527.85 | |
| 51798 | <1% | 336 | $525.29 | |
| 84450 | <1% | 101 | $517.15 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,736 | $504.22 |
| 72040 | <1% | 120 | $461.12 | |
| 73590 | <1% | 15 | $459.42 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,169 | $436.70 |
| C1769 | Guide wire | <1% | 111 | $425.21 |
| 87634 | <1% | 25 | $413.95 | |
| 85384 | <1% | 29 | $410.96 | |
| 80143 | <1% | 39 | $381.22 | |
| 86800 | <1% | 28 | $350.60 | |
| 85018 | <1% | 1,417 | $343.86 | |
| 72050 | <1% | 12 | $338.30 | |
| 86480 | <1% | 128 | $337.87 | |
| 82105 | <1% | 294 | $325.14 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,505 | $323.18 |
| 29515 | <1% | 34 | $317.14 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 230 | $309.60 |
| 90686 | <1% | 322 | $296.74 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 449 | $287.98 |
| V2632 | Posterior chamber intraocular lens | <1% | 296 | $260.73 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 627 | $228.77 |
| 73090 | <1% | 31 | $227.37 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,819 | $214.67 |
| 36591 | <1% | 117 | $191.93 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 98 | $190.09 |
| 84132 | <1% | 369 | $187.39 | |
| 86708 | <1% | 168 | $150.44 | |
| 86160 | <1% | 51 | $149.16 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 460 | $138.01 |
| 86141 | <1% | 14 | $127.48 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 465 | $121.86 |
| 82247 | <1% | 172 | $120.51 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,079 | $103.93 |
| 96368 | <1% | 376 | $102.81 | |
| 86308 | <1% | 35 | $101.14 | |
| 86696 | <1% | 286 | $99.35 | |
| 86695 | <1% | 286 | $91.23 | |
| 86704 | <1% | 338 | $81.60 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 125 | $79.88 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,128 | $73.08 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 52 | $62.89 |
| 80178 | <1% | 88 | $62.89 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 279 | $56.84 |
| G0008 | Administration of influenza virus vaccine | <1% | 680 | $56.31 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 563 | $56.11 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 191 | $54.00 |
| 77066 | Tomosynthesis, mammo | <1% | 624 | $52.20 |
| 82465 | <1% | 16 | $48.02 | |
| 82272 | <1% | 14 | $46.75 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 149 | $42.06 |
| J9370 | Vincristine sulfate, 1 mg | <1% | 24 | $33.99 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $29.12 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 450 | $28.06 |
| 10060 | <1% | 42 | $26.43 | |
| 84165 | <1% | 106 | $24.01 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 88 | $17.84 |
| 84295 | <1% | 116 | $17.21 | |
| 90682 | <1% | 188 | $13.89 | |
| 80305 | <1% | 443 | $11.97 | |
| 84155 | <1% | 107 | $8.28 | |
| 77336 | <1% | 515 | $3.33 | |
| 77065 | Tomosynthesis, mammo | 0% | 553 | $0.00 |
| 93296 | 0% | 995 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 2,475 | $0.00 |
| 71271 | 0% | 171 | $0.00 | |
| 81002 | 0% | 1,287 | $0.00 | |
| 43249 | 0% | 161 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 39 | $0.00 |
| 77334 | 0% | 107 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 94 | $0.00 |
| 99490 | Ccm add 20min | 0% | 137 | $0.00 |
| 80164 | 0% | 110 | $0.00 | |
| 90662 | 0% | 88 | $0.00 | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | 0% | 42 | $0.00 |
| 86703 | 0% | 1,333 | $0.00 | |
| 98929 | 0% | 472 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 38 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 216 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 78 | $0.00 |
| 36592 | 0% | 105 | $0.00 | |
| 77080 | 0% | 438 | $0.00 | |
| 93299 | 0% | 32 | $0.00 | |
| 51741 | 0% | 61 | $0.00 | |
| 86709 | 0% | 70 | $0.00 | |
| 93226 | 0% | 31 | $0.00 | |
| 76813 | 0% | 13 | $0.00 | |
| 96523 | 0% | 16 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 12 | $0.00 |
| 86923 | 0% | 17 | $0.00 | |
| 93321 | 0% | 15 | $0.00 | |
| 0124A | 0% | 13 | $0.00 | |
| 88360 | 0% | 13 | $0.00 | |
| 49083 | 0% | 82 | $0.00 | |
| 93970 | 0% | 12 | $0.00 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 14 | $0.00 |
| 93225 | 0% | 30 | $0.00 | |
| 91320 | 0% | 16 | $0.00 | |
| 72070 | 0% | 14 | $0.00 | |
| 95909 | 0% | 14 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 25 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 12 | $0.00 |
| 93798 | 0% | 90 | $0.00 | |
| 94729 | 0% | 14 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 32 | $0.00 |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 0% | 13 | $0.00 |
| 72197 | 0% | 28 | $0.00 | |
| 88173 | 0% | 32 | $0.00 | |
| 98926 | 0% | 53 | $0.00 | |
| 87641 | 0% | 35 | $0.00 | |
| 86999 | 0% | 13 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 22 | $0.00 |
| 20552 | 0% | 14 | $0.00 | |
| 90837 | Psychotherapy session, about an hour | 0% | 75 | $0.00 |
| 84112 | 0% | 14 | $0.00 | |
| 17110 | 0% | 17 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 19 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 335 | $0.00 |
| 29581 | 0% | 338 | $0.00 | |
| J0185 | Injection, aprepitant, 1 mg | 0% | 788 | $0.00 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 452 | $0.00 |
| 95886 | 0% | 103 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 2,461 | $0.00 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 0% | 140 | $0.00 |
| 84144 | 0% | 71 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 1,629 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 19 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 89 | $0.00 |
| 20610 | 0% | 52 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 68 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 203 | $0.00 |
| J1335 | Injection, ertapenem sodium, 500 mg | 0% | 37 | $0.00 |
| 76801 | 0% | 75 | $0.00 | |
| 77300 | 0% | 12 | $0.00 | |
| 84153 | 0% | 380 | $0.00 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 83 | $0.00 |
| 83521 | 0% | 80 | $0.00 | |
| 64483 | 0% | 302 | $0.00 | |
| 82378 | 0% | 231 | $0.00 | |
| 64615 | 0% | 73 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 14 | $0.00 |
| 86769 | 0% | 26 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 19 | $0.00 |
| 99439 | 0% | 16 | $0.00 | |
| 72146 | 0% | 15 | $0.00 | |
| 97165 | 0% | 13 | $0.00 | |
| 73564 | 0% | 24 | $0.00 | |
| 86300 | 0% | 58 | $0.00 | |
| 76820 | 0% | 32 | $0.00 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 14 | $0.00 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 0% | 15 | $0.00 |
| 71101 | 0% | 17 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 41 | $0.00 |
| 94010 | 0% | 28 | $0.00 | |
| 64493 | 0% | 31 | $0.00 | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 0% | 55 | $0.00 |
| 77001 | 0% | 15 | $0.00 | |
| 99495 | 0% | 12 | $0.00 | |
| 90480 | 0% | 20 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 16 | $0.00 |
| 82553 | 0% | 47 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 20 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 26 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 13 | $0.00 |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | 0% | 42 | $0.00 |
| 87807 | 0% | 26 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 13 | $0.00 |
| 73120 | 0% | 13 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 15 | $0.00 |
| 81005 | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABEL, KEVIN (PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.